This post was originally published on this site
Addiction Recovery Bulletin
SO THEY SAY –
July 22, 2024 – Close to 30 percent of the estimated 280 million people in the world living with major depressive disorder have treatment resistant depression. Sales of Spravato soared 60% to $271 million in the three months ended June 30, compared with the same period in 2023. Spravato has been used by 100,000 people in 77 countries, according to Johnson & Johnson. Spravato is administered as nasal spray and must be taken under the supervision of a healthcare provider in a healthcare setting. Unlike, other antidepressants that regulate chemicals like serotonin and dopamine in the brain, Spravato works by boosting glutamate in the brain. Glutamate is the most abundant neurotransmitter in the brain and helps neurons communicate with each other.
CONTINUE@Quartz
The post Johnson & Johnson’s Ketamine-Based Drug Treats Depression appeared first on Addiction/Recovery eBulletin.